COMMUNIQUÉS West-GlobeNewswire

Sanuwave Announces Q3 FY2025 Financial Results
07/11/2025
Q3 2025 revenues were $11.5 million , up 22% from $9.4 million in Q3 2024. This represents the highest quarterly revenues in Company history. Q3 2025 gross margin was 77.9% , versus 75.5% in Q3 2024. GAAP Operating [...]
Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
07/11/2025
Reports third quarter 2025 total revenue of $7.8 million , representing 3% growth compared to the third quarter of 2024. Third quarter 2025 recurring revenue, which includes consumables and annual service contracts, [...]
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
07/11/2025
Net income of $5.9 million and $11.2 million for the three and nine months ended September 30, 2025, respectively Full-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to [...]
Nonprofit Human Appeal Launches Winter Coat Drive Across US East Coast
07/11/2025
Human Appeal’s first U.S. domestic campaign aims to collect 3,500 coats for families in need FAIRFAX, Va., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Global humanitarian aid nonprofit Human Appeal has officially launched its [...]
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
07/11/2025
Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjusted non-GAAP EBITDA [...]
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
07/11/2025
GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related discontinuations Dose dependent [...]
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
07/11/2025
Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in compensated cirrhosis ( [...]
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
07/11/2025
Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors MIRAMAR, Fla., Nov. 07 [...]
Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025
07/11/2025
Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scale REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq [...]
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
07/11/2025
-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate [...]
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
BEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has [...]
Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Re-source Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting
07/11/2025
PRESS RELEASE Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant [...]
SAFE - Suivi de sortie de la procédure de redressement judiciaire - Report de publication des résultats 2024
07/11/2025
Fleurieux-sur-l’Arbresle – France – 7 novembre 2025 – Dans le cadre de sa sortie de procédure de redressement judiciaire, Safe (FR0014002U25 – ALSAF) s'est rendue, ce jour, au Palais de Justice de Pontoise afin de [...]
Notification of managers’ transactions
07/11/2025
ANNOUNCEMENT NO. 297 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Notification of managers’ transactions
07/11/2025
ANNOUNCEMENT NO. 298 7 November 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in [...]
Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
07/11/2025
PMA submission targeted for Q1 2026 following positive Tigris results and ongoing FDA interactions Company to host Corporate Update call on Wednesday, December 10, 2025 TORONTO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
07/11/2025
S ingle ascending dose data readout for VTP-1000 expected before the end of 2 025 Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026 Proposed combination [...]
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
07/11/2025
-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial- [...]
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
07/11/2025
CLEVELAND, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it will host a conference call on Wednesday, November 12, 2025 at 8:30 a.m. ET to discuss its third quarter 2025 [...]

Pages